For a subgroup of the patients, the hazard ratio for overall survival in late-stage pancreatic cancer patients taking Incyte Corporation (NASDAQ:INCY)'s Jakafi and Roche's Xeloda...
Keep Reading →
August 23 - News
To the average investor, there are plenty of gauges investors can use to track Mr. Market. Some of the most useful are hedge fund and insider trading interest.
Keep Reading →
August 22 - News
One of the hottest stocks on the market Wednesday was Incyte Corporation (NASDAQ:INCY), a pharmaceutical company specializing in the development of JAK inhibitors.
Keep Reading →
August 22 - News
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis...
Keep Reading →
August 21 - News
Now, according to many traders, hedge funds are seen as delayed, outdated investment tools of an era lost to time.
Keep Reading →
August 21 - News
Incyte Corporation (NASDAQ:INCY) today announced positive results from a phase 2 study of its drug Jakafi in treating refractory metastatic pancreatic cancer.
Keep Reading →
August 21 - News
It's a disease that doesn't often find itself in the spotlight, but multiple sclerosis is quickly becoming an ailment that drugmakers are focusing their efforts on to make a quality...
Keep Reading →
August 19 - News
The buyout drama surrounding cancer drug maker Onyx Pharmaceuticals, Inc.
Keep Reading →
August 16 - News
Pharmaceutical companies are always looking for competitive advantages.
Keep Reading →
August 13 - News
GlaxoSmithKline plc (ADR) (NYSE:GSK) has been accused of making illegal payments to Chinese doctors and government officials by siphoning them through travel agencies.
Keep Reading →
August 12 - News
Ariad Pharmaceuticals, Inc.
Keep Reading →
August 8 - News
Investors might want to keep their eyes on the eye care industry, as the battle for eye treatments heats up across the biotech sector.
Keep Reading →
August 8 - News
Chronic obstructive pulmonary disease (COPD) is America’s third leading cause of death.
Keep Reading →
August 5 - News
The biotechnology industry is one of the riskiest places to put your money. However, when companies get everything right, the fortunes made there are usually massive.
Keep Reading →
August 5 - News
The investing waters can get pretty choppy from time to time with a developmental stage company. A look at the five-year chart of Momenta Pharmaceuticals, Inc.
Keep Reading →
August 2 - News
Astex Pharmaceuticals, Inc. (NASDAQ:ASTX) announced its second-quarter financial results on Thursday prior to the market open.
Keep Reading →
August 2 - News
It isn't very often that an agency sometimes accused of over-regulating an industry can be ridiculed for not regulating enough, but that's exactly where the Food and Drug Administration...
Keep Reading →
August 2 - News
Budding biotech company Incyte Corporation (NASDAQ:INCY), which specializes in developing novel JAK inhibitors, released solid second-quarter earnings on Wednesday.
Keep Reading →
August 1 - News
Hidden beneath all the numbers and metrics in Biogen Idec Inc (NASDAQ:BIIB)'s recent earnings report is a key confirmation of a shifting market in the treatment of multiple sclerosis...
Keep Reading →
August 1 - News
To most people, cigarettes are often associated with lung cancer.
Keep Reading →
July 30 - News
The biotech industry is known for fast paced acquisitions and rapid market consolidation.
Keep Reading →
July 29 - News
The United States Court of Appeals is making this one miserable summer for Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA).
Keep Reading →
July 29 - News
The aging population as well as the higher number of people who will receive benefits under new healthcare laws should combine to produce rising profits for a variety of companies...
Keep Reading →
July 29 - News
Onyx Pharmaceuticals, Inc. (NASDAQ:ONXX) added 3% to its one-month 60% gains on Monday because of continued speculation of a buyout.
Keep Reading →
July 24 - News
With the SPDR S&P Biotech Index up 31% over the trailing-12-month period, it's evident that investment dollars are willingly flowing into the biotech sector.
Keep Reading →
July 22 - News
The story of the second quarter for Novartis AG (ADR) (NYSE:NVS) offered mixed results for investors. The company's net sales were up 1%, and EPS was down 6% year over year.
Keep Reading →
July 18 - News
Amid sluggish sales growth, the Pharmaceutical Industry giants are struggling with declining revenues and profits.
Keep Reading →
July 18 - News
Sustainability and a strong pipeline are the two tests that best evaluate a pharmaceutical company. Merck & Co., Inc. (NYSE:MRK) scores high on both counts.
Keep Reading →
July 18 - News
Over 13 million Americans have it. More than 120,000 of them die every year.
Keep Reading →
July 17 - News
Ineffective drugs being sold for billions in global sales.
Keep Reading →
July 16 - News
The U.S. military has a reputation as a somewhat secretive organization. But in one respect at least, the Pentagon ranks among our most transparent government agencies.
Keep Reading →
July 8 - News
Love it or hate it, the Patient Protection and Affordable Care Act -- commonly referred to as Obamacare -- changes the health care landscape.
Keep Reading →
July 5 - News
Healthcare stocks have rallied over the past couple years, and for good reason.
Keep Reading →
June 28 - News
It is expected that the death rate from diabetes will top 50% in the next ten years, which will make it a leading cause of death worldwide.
Keep Reading →
June 28 - News
There are investment opportunities in every sector, but biotechs launching new drugs offer a unique investment opportunity to take advantage of hyper-growth as sales increase ...
Keep Reading →
June 27 - News
Johnson & Johnson (NYSE:JNJ) stands alone as a leader across the major health-care industries.
Keep Reading →
June 27 - News
Medical firm Johnson & Johnson (NYSE:JNJ) recently announced a private-company acquisition that could have major implications for one of the markets in which it operates.
Keep Reading →
June 25 - News
Pfizer Inc. (NYSE:PFE) was in 81 hedge funds' portfolio at the end of the first quarter of 2013. PFE shareholders have witnessed an increase in hedge fund interest recently.
Keep Reading →
June 24 - News
Shares of small biotech Idenix Pharmaceuticals Inc (NASDAQ:IDIX) took a 32% nosedive this week, following unwelcome news from the U.S. Food and Drug Administration.
Keep Reading →
June 24 - News
It’s not easy being a biotech company.
Keep Reading →
June 18 - News
The Food and Drug Administration (FDA) made a groundbreaking policy change last year that is having a large impact on the biotech industry and creating a big opportunity for...
Keep Reading →
June 17 - Stock Analysis
After a year-long dream run, Biogen Idec Inc. (NASDAQ:BIIB) lost 5.25% in the week ended Friday, June 7.
Keep Reading →
June 17 - News
Investors in a handful of health-care stocks are probably all smiles this week. Several stocks saw nice double-digit gains over the past five days.
Keep Reading →
June 17 - News
Recently, AstraZeneca plc (ADR) (NYSE:AZN) announced that it has agreed to acquire Pearl Therapeutics, the respiratory drug manufacturer, in a transaction worth around $1.15 billion...
Keep Reading →
June 17 - News
Investing in biotech stocks is relatively risky amid the volatility of the market. There are many factors that can greatly affect share trends and price performance.
Keep Reading →
June 13 - News
Generic-drug makers are always on the hunt for the next branded drug to take down.
Keep Reading →
June 13 - News
While the debate goes on whether increasing output by acquiring new businesses through mergers, acquisitions and takeovers is the right way forward, the biopharmaceutical industry...
Keep Reading →
June 13 - News
Valeant Pharmaceuticals Intl Inc (NYSE:VRX) has been on an acquisition spree. Its latest purchase is Bausch + Lomb in an all-cash deal worth $8.7 billion.
Keep Reading →
June 12 - News
Merck & Co., Inc. (NYSE:MRK) has been trying to generate more value for its shareholders via its share buyback program.
Keep Reading →
June 12 - News
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis...
Keep Reading →
June 11 - News
